Eosinophil-mediated inflammation in the absence of eosinophilia
- PMID: 34386406
- PMCID: PMC8331253
- DOI: 10.5415/apallergy.2021.11.e30
Eosinophil-mediated inflammation in the absence of eosinophilia
Abstract
The increase of eosinophil levels is a hallmark of type-2 inflammation. Blood eosinophil counts act as a convenient biomarker for asthma phenotyping and the selection of biologics, and they are even used as a prognostic factor for severe coronavirus disease 2019. However, the circulating eosinophil count does not always reflect tissue eosinophilia and vice versa. The mismatch of blood and tissue eosinophilia can be seen in various clinical settings. For example, blood eosinophil levels in patients with acute eosinophilic pneumonia are often within normal range despite the marked symptoms and increased number of eosinophils in bronchoalveolar lavage fluid. Histological studies using immunostaining for eosinophil granule proteins have revealed the extracellular deposition of granule proteins coincident with pathological conditions, even in the absence of a significant eosinophil infiltrate. The marked deposition of eosinophil granule proteins in tissue is often associated with cytolytic degranulation. Recent studies have indicated that extracellular trap cell death (ETosis) is a major mechanism of cytolysis. Cytolytic ETosis is a total cell degranulation in which cytoplasmic and nuclear contents, including DNA and histones that act as alarmins, are also released. In the present review, eosinophil-mediated inflammation in such mismatch conditions is discussed.
Keywords: Eosinophil granule proteins; Eosinophils; Extracellular traps.
Copyright © 2021. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.
Conflict of interest statement
Conflict of interest: MF received grant support from GlaxoSmithKline Japan Research Grants 2018; PA has received research support and consultancy fees from and has been on advisory boards for AstraZeneca and GlaxoSmithKline; SU received honoraria for lectures from AstraZeneca and GlaxoSmithKline as well as grant support from AstraZeneca, Novartis, and Maruho. The rest of the authors have no conflicts of interest.
Figures
References
-
- Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–836. - PubMed
-
- Ueki S, Kihara J, Kato H, Ito W, Takeda M, Kobayashi Y, Kayaba H, Chihara J. Soluble vascular cell adhesion molecule-1 induces human eosinophil migration. Allergy. 2009;64:718–724. - PubMed
-
- Gouon-Evans V, Pollard JW. Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology. 2001;142:4515–4521. - PubMed
-
- Tamaki M, Konno Y, Kobayashi Y, Takeda M, Itoga M, Moritoki Y, Oyamada H, Kayaba H, Chihara J, Ueki S. Expression and functional roles of G-protein-coupled estrogen receptor (GPER) in human eosinophils. Immunol Lett. 2014;160:72–78. - PubMed
Publication types
LinkOut - more resources
Full Text Sources